IRIDEX (NASDAQ:IRIX) Stock: Insider Shih-Yao David Lin Acquires 15,755 Shares

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin acquired 15,755 shares of IRIDEX stock in a transaction that occurred on Monday, June 9th. The stock was acquired at an average cost of $0.99 per share, with a total value of $15,597.45. Following the purchase, the insider owned 604,100 shares in the company, valued at $598,059. The trade was a 2.68% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

IRIDEX Stock Performance

IRIX opened at $0.90 on Friday. The company has a market cap of $15.78 million, a PE ratio of -4.49 and a beta of 0.67. The stock has a 50-day moving average of $0.73 and a 200-day moving average of $0.95. IRIDEX Corporation has a 52-week low of $0.61 and a 52-week high of $1.65.

IRIDEX (NASDAQ:IRIX) last posted its earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06). The company had revenue of $12.57 million for the quarter, compared to analyst estimates of $13.59 million. On average, research analysts predict that IRIDEX Corporation will post -0.12 earnings per share for the current year.

Institutional Trading of IRIDEX

Several institutional investors have recently bought and sold shares of IRIX. Renaissance Technologies LLC boosted its stake in IRIDEX by 6.7% in the 1st quarter. Renaissance Technologies LLC now owns 396,627 shares of the medical equipment provider’s stock valued at $401,000 after buying an additional 25,067 shares in the last quarter. Weber Capital Management LLC ADV acquired a new position in IRIDEX during the second quarter worth $206,616. Perkins Capital Management Inc. lifted its holdings in shares of IRIDEX by 33.9% during the first quarter. Perkins Capital Management Inc. now owns 55,300 shares of the medical equipment provider’s stock valued at $56,000 after acquiring an additional 14,000 shares during the period. Thompson Davis & CO. Inc. lifted its holdings in shares of IRIDEX by 66.5% during the first quarter. Thompson Davis & CO. Inc. now owns 47,444 shares of the medical equipment provider’s stock valued at $48,000 after acquiring an additional 18,944 shares during the period. Finally, United Capital Financial Advisors LLC bought a new position in shares of IRIDEX during the second quarter valued at $41,000. Institutional investors and hedge funds own 20.10% of the company’s stock.

Trending Headlines about IRIDEX

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: Lin reported another purchase of 10,000 IRIX shares at an average price of $1.05, worth $10,500. The transaction increased his direct holdings to 735,561 shares. IRIDEX major shareholder buys 10,000 shares
• Positive Sentiment: SEC disclosures show a sustained accumulation campaign by Lin, including purchases of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00, along with numerous other transactions. Repeated buying by a major shareholder may signal confidence in IRIDEX’s longer-term prospects and can support momentum in a low-market-cap stock. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: Several institutional investors also increased positions, including Perkins Capital Management, Thompson Davis, and Renaissance Technologies. Institutions own approximately 20.1% of IRIDEX’s shares, providing additional ownership support, though their disclosed positions remain relatively small in dollar terms.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down pause. The halt underscores unusually high volatility and the possibility of sharp price reversals when trading resumes.
• Neutral Sentiment: Analyst sentiment remains mixed: one analyst rates the stock Buy and another Sell, resulting in a consensus Hold rating. The reported consensus price target is $3.00, but the limited coverage reduces its reliability.
• Negative Sentiment: IRIDEX’s latest reported quarter remains a fundamental concern. The company posted a $0.07-per-share loss versus a $0.01 expected loss and revenue of $12.57 million versus the $13.59 million consensus estimate. Analysts expect a full-year loss of approximately $0.12 per share.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 2nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $3.00.

IRIDEX Company Profile

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.